HTA Database - Search Results

Sort by Relevance

Search Results [15895 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Benefit assessment of medicinal products with new active ingredients according to section 35a SGB V: Blinatumomab (new therapeutic indication: B-precursor acute lymphoblastic leukaemia, relapsed or refractory, Ph+ CD19+)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bulevirtide (chronic hepatitis delta virus (HDV) infection)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Crizanlizumab (repeal of the resolution of 20 May 2021)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fedratinib (myelofibrosis)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Glasdegib (acute myeloid leukaemia (AML), combination with cytarabine (LDAC))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Imlifidase (desensitisation in kidney transplantation)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (Exceeding the € 50 Million Limit, Cystic Fibrosis, Combination Treatment with Ivacaftor in Patients 12 Years and Older (Heterozygous for F508del and MF Mutation))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (exceeding the € 50 million limit, cystic fibrosis, combination treatment with Ivacaftor in patients 12 years and older (homozygous for F508del mutation))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Lumasiran (Hyperoxaluria)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Luspatercept (Myelodysplastic Syndrome (MDS))]
2021	Malaysian Health Technology Assessment (MaHTAS)	Hyperthermic intraperitoneal chemotherapy as an adjuvant therapy for peritoneal surface malignancy (PSM)
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Luspatercept (β-thalassaemia)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Osilodrostat (Endogenous Cushing’s Syndrome)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Pemigatinib (cholangiocarcinoma with FGFR2 fusion or FGFR2 rearrangement, after at least one prior therapy)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Sebelipase alfa (reassessment after expiry of the deadline (lysosomal acid lipase deficiency))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tagraxofusp (blastic plasmacytoid dendritic cell neoplasm, first-line)]
2021	Malaysian Health Technology Assessment (MaHTAS)	HPV vaccine - an update
2021	Norwegian Institute of Public Health (NIPH)	[Medpor polyethylene implant in reconstructive ear surgery in patients with microtia: rapid health technology assessment]
2021	Norwegian Institute of Public Health (NIPH)	[Description and quality assessment of guidelines for tonsillectomy in patients with recurrent tonsillitis: mapping review]
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance on protective measures for vulnerable groups in the context of COVID-19
2021	Health Information and Quality Authority (HIQA)	Rolling summary of the evidence in relation to the Omicron (B.1.1.529) variant
2021	Health Information and Quality Authority (HIQA)	Use of respirator masks by persons who are at higher risk from COVID-19
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance for residential care facilities in the context of COVID-19
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prevention of tuberculosis reactivation
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Yttrium-90 microspheres for intermediate- or advanced-stage hepatocellular carcinoma
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Abiraterone acetate for metastatic castration-sensitive prostate cancer
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bisphosphonate drugs for the treatment of osteoporosis in post-menopausal women
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Direct oral anticoagulants for atrial fibrillation [evidence update]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interventions to address and prevent violence toward health care workers in the emergency department
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Hybrid closed-loop insulin delivery systems for people with Type 1 diabetes
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Stereotactic ablative radiotherapy for the treatment of oligometastatic cancer: a clinical review as part of a health technology assessment v1.0
2021	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Treatment for postpartum psychiatric disorders - an evidence map]
2021	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Identification of factors influencing the risk of absconding in a user with an intellectual disability, autism spectrum disorder or a mental health disorder]
2021	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Evaluation of the service offer from the Centre d'expertise pour les victimes de brûlures graves de l'est du Québec (CEVBGEQ) in relation to the use of pressure garments to treat scarring in severe burn patients]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Venous irritation resulting from IV fosaprepitant
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Oral hygiene interventions to prevent ventilator-associated pneumonia (VAP)
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cabozantinib (reassessment after the deadline: thyroid carcinoma)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Brentuximab Vedotin (reassessment after the deadline: systemic anaplastic large cell lymphoma; first-line; combination with Cyclophosphamide, Doxorubicin, and Prednisone)]
2021	Malaysian Health Technology Assessment (MaHTAS)	Delirium unit in geriatric ward
2021	Basque Office for Health Technology Assessment (OSTEBA)	[Efficacy of high flow oxygen therapy for the treatment of respiratory distress in children]
2021	Austrian Institute for Health Technology Assessment (AIHTA)	The economic and societal dimension of parental mental illness. Part 1: systematic review. Part II: economic evaluation framework
2021	Austrian Institute for Health Technology Assessment (AIHTA)	≥ 12 month follow-up of patients with spinal muscular atrophy (SMA) treated with Spinraza®, Zolgensma® or combination therapies
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Equine immunoglobulin F(ab’)2 fragments (hyperimmune equine serum) for COVID-19]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ivermectin for COVID-19]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Flash glucose monitoring system in diabetes mellitus patients]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ketogenic diet in central nervous system tumors]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Teduglutide in short bowel syndrome]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dipeptidyl-peptidase 4 inhibitors in patients with prediabetes or metabolic syndrome]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Tolvaptan in autosomal dominant polycystic kidney disease]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Tocilizumab in COVID-19 patients]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Allocation of scarce resources in critical care units in a pandemic]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[SGLT2 inhibitors in heart failure]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ambulatory oxygen therapy in COVID-19]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Eye controlled speech generating device]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Risdiplam in spinal muscular atrophy]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Stem cell therapy: clinical applications]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Non-invasive respiratory support in Covid-19 patients]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Brolucizumab in neovascular age-related macular degeneration]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[COVID-19: follow-up after an acute episode]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Microperimetry in retinopathies]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cardiopulmonary resuscitation in COVID-19 patients]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Patisiran and inotersen in hereditary transthyretin-mediated amyloidosis]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Whole-exome sequencing in patients with neurological disorders]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Transcatheter aortic valve implantation in severe aortic stenosis]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Swallowable gastric balloon in obesity]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Whole exome sequencing in patients with intellectual disability and/or autism spectrum disorder]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Extracranial stereotactic body radiotherapy in oligometastasis]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Whole exome sequencing in epileptic encephalopathies]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Baricitinib in COVID-19 patients]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Edaravone in patients with amyotrophic lateral sclerosis]
2021	Canary Health Service	[Framework for relations between the Spanish Network of HTA agencies of the NHS with industry]
2021	Canary Health Service	[Effectiveness of measures to close or restrict occupancy in ceremonial and worship places in the context of the SARS-CoV-2 pandemic]
2021	Health Sciences Institute in Aragon (IACS)	[Congenital ventricular septal defect (VSD) treatment with percutaneous and periventricular insertion devices]
2021	Health Information and Quality Authority (HIQA)	Analysis of factors associated with outbreaks of SARS-CoV-2 in nursing homes in Ireland
2021	Canary Health Service	[Effectiveness of measures to close or restrict occupancy in cultural and entertainment places, in the context of the SARS-CoV-2 pandemic]
2021	Institute of Health Economics (IHE)	Optimizing vascular risk reduction initiatives in Alberta: a clinical review and economic analysis
2021	Canary Health Service	[Effectiveness and cost-effectiveness of universal eating disorders prevention in children, preadolescents and adolescents at school]
2021	Adelaide Health Technology Assessment (AHTA)	Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021	Adelaide Health Technology Assessment (AHTA)	Immunoglobulin for chronic inflammatory demyelinating polyneuropathy
2021	Adelaide Health Technology Assessment (AHTA)	Genomic testing for the diagnosis of heritable cardiomyopathies
2021	Andalusian Health Technology Assessment Area (AETSA)	[Clinical utility of optical coherence tomography angiography in exudative age-related macular degeneration management]
2021	Andalusian Health Technology Assessment Area (AETSA)	[High intensity focused ultrasound (HIFU) in organ-confined prostate tumors]
2021	Malaysian Health Technology Assessment (MaHTAS)	Targeted therapies in combination with neoadjuvant chemotherapy for HER2-positive breast cancer and economic evaluation
2021	Malaysian Health Technology Assessment (MaHTAS)	Therapeutic drug monitoring (TDM) for anti-tuberculosis
2021	Malaysian Health Technology Assessment (MaHTAS)	Custodiol HTK as a replacement of blood cardioplegia in cardiac surgery
2021	Malaysian Health Technology Assessment (MaHTAS)	Mobile C-arm fluoroscopy for cardiothoracic surgery
2021	Malaysian Health Technology Assessment (MaHTAS)	Viscoelastic haemostatic assay for non-cardiac surgery
2021	Malaysian Health Technology Assessment (MaHTAS)	Driving simulator in healthcare
2021	Malaysian Health Technology Assessment (MaHTAS)	Digital assisted oral & cranio-maxillofacial surgery
2021	Malaysian Health Technology Assessment (MaHTAS)	Platelet rich plasma (PRP), platelet-rich fibrin (PRF) and concentrated growth factor (CGF) for treatment of periodontal disease
2021	Scottish Health Technologies Group (SHTG)	Minuteful Kidney for home testing of albumin-to-creatine ratio (ACR)
2021	Scottish Health Technologies Group (SHTG)	Chest wall bracing for children and young people with pectus carinatum
2021	Agency for Care Effectiveness (ACE)	MRI-US fusion targeted biopsy for diagnosis of prostate cancer
2021	Agency for Care Effectiveness (ACE)	Transcatheter mitral valve leaflet repair for patients with mitral regurgitation
2021	Agency for Care Effectiveness (ACE)	Transcatheter aortic valve implantation (TAVI) for patients with symptomatic severe aortic stenosis
2021	Agency for Care Effectiveness (ACE)	Photodynamic therapy for treating non-melanoma skin tumours
2021	Agency for Care Effectiveness (ACE)	Cochlear implants for treating adults with single-sided deafness (SSD)
2021	Agency for Care Effectiveness (ACE)	Antibacterial envelope for the prevention of cardiac implantable electronic device-related infections